IgA Antibody RBD Recognition in Automated Chemiluminescence Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid detection methods for COVID-19 face high false-negative rates due to low RNA abundance and sample contamination, posing infection risks and requiring skilled personnel, while IgA antibody detection is hindered by competitive binding with IgM and IgG, necessitating an accurate and safe calibrator for IgA antibody measurement.
Innovation Solution
Development of a humanized IgA antibody with specific binding affinity to the RBD protein of SARS-CoV-2, used in a chemiluminescence kit for automated, high-throughput detection, utilizing recombinant RBD protein and secondary antibodies to enhance sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid detection is performed using real-time fluorescent RT-PCR, then diagnosis can be confirmed, but false-negative rate increases due to low RNA abundance and sample contamination
Solution Approach 1:
The patent uses recombinant RBD protein as an intermediary antigen in a chemiluminescence immunoassay to detect IgA antibodies. This intermediary approach converts direct viral RNA detection into indirect antibody detection, avoiding the low sensitivity problems of RNA detection while maintaining diagnostic accuracy through detection of the host immune response to the virus.
Solution Approach 2:
The patent replaces the mechanical/nucleic acid-based RT-PCR detection system with an immunological chemiluminescence detection system. This substitution uses antibody-antigen binding and chemiluminescence reactions instead of nucleic acid amplification, thereby avoiding contamination issues and improving detection reliability through a different detection mechanism.
2Reliability
If IgA antibody detection is performed using conventional methods, then diagnosis can be assisted, but detection accuracy decreases due to competitive binding with IgM and IgG antibodies
Solution Approach 1:
The patent applies local quality by using a specific recombinant RBD protein antigen that selectively binds to IgA antibodies with high affinity. The localized epitope design in the RBD protein creates a specific binding site that reduces cross-reactivity with IgM and IgG, enabling precise IgA detection even in the presence of other antibody types.
3Reliability
If blood sampling is performed for nucleic acid detection, then RNA can be extracted for testing, but infection risk increases for sample collection personnel
Solution Approach 1:
The patent uses serum or plasma as an intermediary sample type instead of direct viral sampling. This intermediary approach allows detection of IgA antibodies that indicate recent infection, providing diagnostic information without requiring personnel to handle highly infectious viral samples, thereby reducing infection risk while maintaining diagnostic reliability.
4Reliability
If conventional IgM reagents are used for detection, then early infection can be detected, but false positive or false negative outcomes occur
Solution Approach 1:
The patent changes the detection parameter from IgM antibody detection to IgA antibody detection. This parameter change leverages the different kinetics and specificity of IgA antibodies, which appear early in infection and provide more reliable diagnostic information with fewer false positives or negatives compared to conventional IgM reagents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IgA antibody kit provides accurate, rapid, and automated detection of COVID-19 with high sensitivity and specificity, reducing false negatives and infection risks, and enabling early diagnosis through IgA antibody measurement.
Implementation Method 1
the indirect methods in which an antigen is coated on the surface of a solid phase allows for the rapid enrichment of the antibody to be tested according to the immunological principle of antigen-antibody binding
Implementation Method 2
the chemiluminescence technology is used for the detection of chemiluminescence intensity mainly based on the principle that the concentration of the analyte in the detection system is in a quantitatively linear relationship with the chemiluminescence intensity of the system
Data Source
AI summary
The disclosure relates to the technical field of virus detection, in particular, to an IgA antibody and a kit capable of specifically recognizing RBD protein. The antibody can be used as a calibrator of IgA antibody against the RBD protein of SARS-CoV-2. the disclosure further relates to a kit comprising the antibody which enables automated, high-throughput, and rapid detection of IgA antibody against novel coronavirus pneumonia.